----item----
version: 1
id: {B5499C45-7C02-41B2-A6E7-8EFBD52ADBEB}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/AllStories/2015/01/28/FDA OKs LillyBI dual mechanism diabetes drug Glyxambi
parent: {EC2A1187-1377-4ECE-B9F1-969AB02DB7F3}
name: FDA OKs LillyBI dual mechanism diabetes drug Glyxambi
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: c0f8032a-6a2c-4b07-91c5-cb5237d3e874

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 77

{CD796374-A60A-4D81-8A05-7B92AD2013C1}|{3FA7743D-5DAB-49A3-B30D-DF5079ADB082}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 55

FDA OK's Lilly/BI dual mechanism diabetes drug Glyxambi
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 53

FDA OKs LillyBI dual mechanism diabetes drug Glyxambi
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 2197

<p>Lilly and Boehringer Ingelheim won the FDA's blessing on 2 February to market Glyxambi (empagliflozin/linagliptin) &ndash; the first and only diabetes treatment in the US to combine the dual mechanisms of action of a sodium glucose co-transporter-2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor in a once-daily tablet taken in the morning.</p><p>The drug is approved for use in the US as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when both empagliflozin and linagliptin are appropriate treatments.</p><p>When the companies submitted their application, Sagient Research's <i>BioMedTracker</i>, an affiliate of <i>Scrip</i>, had put the chances of Glyxambi gaining the FDA's approval at 81%, which is same as the average probability of US approval for the same indication based on the historical performance of medicines in the same development phase.</p><p>The companies market Linagliptin, a DPP-4 inhibitor, under the brand name Tradjenta as a once-daily 5mg tablet used along with diet and exercise to improve glycemic control in adults with type 2 diabetes.</p><p>It gained the FDA's approval in May 2011 (scripintelligence.com, <a href="http://www.scripintelligence.com/researchdevelopment/Boehringer-Lilly-win-US-approval-of-Tradjenta-in-Type-II-diabetes-314907" target="_new">3 May 2011</a>).</p><p>The companies market empagliflozin, an SGLT2, under the name Jardiance. It just won the FDA's not this past August (scripintelligence.com, <a href="http://www.scripintelligence.com/home/FDA-OKs-BoehringerLilly-type-2-diabetes-drug-Jardiance-353159" target="_new">1 August 2014</a>).</p><p>Glyxambi is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. </p><p>The FDA approved Glyxambi based on a Phase III trial that evaluated the efficacy and safety of the combination drug versus the individual components in adults with type 2 diabetes who were also taking high-dose metformin.</p><p>In the study, as an add-on to metformin, Glyxambi showed statistically significant reductions in A1C, versus empagliflozin and linagliptin alone at 24 weeks.</p><p><p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 365

<p>Lilly and Boehringer Ingelheim won the FDA's blessing on 2 February to market Glyxambi (empagliflozin/linagliptin) &ndash; the first and only diabetes treatment in the US to combine the dual mechanisms of action of a sodium glucose co-transporter-2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor in a once-daily tablet taken in the morning.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 53

FDA OKs LillyBI dual mechanism diabetes drug Glyxambi
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150128T140000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150128T140000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150128T140000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 10

SC00027705
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 55

FDA OK's Lilly/BI dual mechanism diabetes drug Glyxambi
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

356420
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160127T233856Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

c0f8032a-6a2c-4b07-91c5-cb5237d3e874
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160127T233856Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
